Iovance Biotherapeutics, Inc. IOVA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$353.86M+9.5% | -$390.98M+1.7% | -$397.63M-2.0% | -$389.92M-3.9% | -$375.36M-0.9% | ||
| $12.93M+2.0% | $12.68M+3.7% | $12.23M-0.1% | $12.25M+3.4% | $11.85M-3.3% | ||
| $49.93M-18.9% | $61.58M-23.7% | $80.74M-19.1% | $99.84M-13.5% | $115.36M+5.2% | ||
| -$1.08M+52.0% | -$2.26M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$7.4M-0.6% | ||
| $10.82M-17.5% | $13.11M+19.2% | $10.99M-61.2% | $28.33M-59.9% | $70.7M+2.2% | ||
| —— | —— | —— | —— | $51.48M+16.0% | ||
| $7.18M+208% | -$6.66M+11.4% | -$7.52M— | —— | —— | ||
| $5.63M-80.5% | $28.92M+144% | $11.83M-37.8% | $19.04M-43.8% | $33.84M+295% | ||
| —— | —— | —— | —— | —— | ||
| $23.42M+1.0% | $23.2M-16.3% | $27.72M+1.1% | $27.42M+0.7% | $27.22M+3.3% | ||
| —— | —— | —— | —— | —— | ||
| $10.39M-8.7% | $11.39M-3.8% | $11.84M+3.0% | $11.5M+4.4% | $11.01M+5.5% | ||
| -$9.81M+10.0% | -$10.9M+6.4% | -$11.65M+4.4% | -$12.19M+1.7% | -$12.4M-2.7% | ||
| -$270.79M+10.5% | -$302.41M+6.4% | -$323.14M-6.5% | -$303.41M+9.3% | -$334.39M+5.3% | ||
| $34.23M+1.2% | $33.84M+18.0% | $28.68M+42.5% | $20.13M+53.5% | $13.11M+18.4% | ||
| $276.74M-13.2% | $318.67M-8.1% | $346.92M-15.7% | $411.29M-1.4% | $416.93M-9.5% | ||
| $354M-11.5% | $400M-10.3% | $446M+2.3% | $436M-5.4% | $461M+7.7% | ||
| $43.02M-9.4% | $47.5M— | —— | —— | —— | ||
| $255.88M-16.5% | $306.31M+22.3% | $250.53M+19.6% | $209.53M-39.8% | $348.34M-12.3% | ||
| $5.59M-20.8% | $7.06M-5.8% | $7.49M-43.7% | $13.31M-3.6% | $13.8M+7.3% | ||
| $251.79M-16.3% | $300.77M+21.8% | $246.91M+23.0% | $200.81M-41.0% | $340.4M-12.9% | ||
| —— | —— | —— | $1.32M+189% | $458K+185% | ||
| —— | —— | —— | —— | $37.43M+163% | ||
| $6.18M-14.2% | $7.2M-16.6% | $8.63M-9.9% | $9.58M-4.9% | $10.07M-1.8% | ||
| $23.42M+1.0% | $23.2M-16.3% | $27.72M+1.1% | $27.42M+0.7% | $27.22M+3.3% | ||
| -$137K-158% | $238K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$9.81M+10.0% | -$10.9M+6.4% | -$11.65M+4.4% | -$12.19M+1.7% | -$12.4M-2.7% | ||
| —— | —— | —— | —— | —— | ||
| $12.9M-3.7% | $13.4M— | —— | —— | —— | ||
| $10.39M-8.7% | $11.39M-3.8% | $11.84M+3.0% | $11.5M+4.4% | $11.01M+5.5% | ||
| $354M-11.5% | $400M-10.3% | $446M+2.3% | $436M-5.4% | $461M+7.7% | ||
| —— | —— | —— | -$18.31M-39.0% | -$13.17M-78.9% | ||
| —— | —— | —— | —— | —— | ||
| -$9.81M+10.0% | -$10.9M+6.4% | -$11.65M+4.4% | -$12.19M+1.7% | -$12.4M-2.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$305.02M+9.3% | -$336.24M+4.4% | -$351.82M-8.7% | -$323.54M+6.9% | -$347.5M+4.5% | ||
| -$305.02M+9.3% | -$336.24M+4.4% | -$351.82M-8.7% | -$323.54M+6.9% | -$347.5M+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Iovance Biotherapeutics, Inc. generate?
- Iovance Biotherapeutics, Inc. (IOVA) generated -$270.8M in operating cash flow over the trailing twelve months.
- What is Iovance Biotherapeutics, Inc.'s free cash flow?
- After $34.2M of capital expenditures, Iovance Biotherapeutics, Inc.'s free cash flow was -$305.0M over the trailing twelve months, up 12.2% year over year.
- Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
